NR1H4 and metabolic dysfunction-associated steatotic liver disease: Another IBAT inhibitor SC-435 is found to significantly reduce the liver fat of NAFLD mice, which is associated with liver FXR activation and lipid synthesis inhibition (Rao et al., 2016; Rao et al., 2020).